PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930085
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930085
The global nasal spray market was valued at USD 32.43 billion in 2025 and is projected to grow to USD 35.26 billion in 2026, reaching USD 70.17 billion by 2034, with a CAGR of 8.90% during 2026-2034. North America dominated the market in 2025 with a 44.01% share, driven by the high prevalence of nasal allergies, allergic rhinitis, and sinus infections, alongside the advantages of precise, painless drug delivery and patient convenience.
Nasal sprays are devices designed for nasal drug delivery to treat conditions such as allergic rhinitis, sinus infections, asthma, and central nervous system disorders. Products available in the market include corticosteroids, saltwater solutions, topical decongestants, antihistamines, and others, with corticosteroids being the most widely used due to their efficacy in treating nasal congestion, sneezing, watery eyes, and runny nose.
Impact of COVID-19
The COVID-19 pandemic caused a temporary decline in nasal spray sales due to weakened cold and flu seasons and social distancing measures. For example, GSK plc experienced an 8.3% revenue drop for its Avamys/Veramyst nasal spray in 2020, and AstraZeneca reported a 32.1% decline for Pulmicort nasal spray. However, by 2021, sales began to recover, and in 2022, new product launches contributed to significant revenue growth, setting the stage for the projected market expansion.
Market Trends
Pharmaceutical companies and private organizations are increasingly investing in R&D activities for novel nasal spray formulations. For instance, in 2022, SK Bioscience partnered with IAVI for developing an antiviral nasal spray, receiving a USD 2.2 million grant from the Bill & Melinda Gates Foundation. Rising healthcare expenditure and improved healthcare infrastructure also contribute to this trend.
Growth Drivers
Increasing Prevalence of Respiratory Disorders
Chronic respiratory diseases, including asthma, COPD, occupational lung diseases, and pulmonary hypertension, are rising globally due to factors such as smoking, pollution, and childhood infections. According to the CDC, asthma prevalence increased from 7.4% in 2001 to 7.7% in 2021. Nasal sprays help alleviate symptoms, improve airflow, and enhance patient comfort, driving demand in the market.
Strong Pipeline of Product Approvals
Companies such as GSK plc, Viatris Inc., Emergent Devices, Cipla, and Pfizer are continuously launching new nasal spray products. Notable approvals include naloxone hydrochloride nasal spray for opioid overdose (2023) and ZAVZPRET for acute migraine treatment (2023). Such regulatory approvals boost market growth and accessibility.
Restraining Factors
Side effects from nasal sprays, including nasal dryness, inflammation, congestion, bitter taste, and CNS or cardiovascular risks, may limit adoption. Additionally, the use of compounded drugs not approved by the FDA poses safety risks and can restrain market expansion.
By Product Type:
By Application:
By Age Group:
By Type:
By Distribution Channel:
Competitive Landscape
Key players include GSK plc, Johnson & Johnson Services, Viatris Inc., Emergent Devices, Cipla, Bayer AG, Aurena Laboratories, Aytu Health, Procter & Gamble, and AstraZeneca. Companies focus on product approvals, launches, partnerships, and geographic expansion. Recent developments include OTC naloxone nasal sprays (2023) and antiviral sprays targeting COVID-19.
Conclusion
The global nasal spray market, valued at USD 32.43 billion in 2025, increased to USD 35.26 billion in 2026 and is projected to reach USD 70.17 billion by 2034. Growth is driven by increasing prevalence of respiratory disorders, strong product pipelines, rising adoption of corticosteroids, strategic R&D initiatives, and expanding healthcare infrastructure across key regions.
Segmentation By Product Type
By Application
By Age Group
By Type
By Distribution Channel
By Region